CLOSEOUT LETTER
Zhejiang Medicine Co. Ltd. Xinchang Pharmaceutical Factory
- Recipient:
- Zhejiang Medicine Co. Ltd. Xinchang Pharmaceutical Factory
United States
- Issuing Office:
United States
10903 New Hampshire Avenue | |
November 9, 2017
Mr. Bin Shano
Managing Director
Zhejiang Medicine Co., Ltd. Xinchang Pharmaceutical Factory
98 East Xinchang Dadao Road
Xinchang, Zhejiang 312500
China
Reference: FEI 3003631275
Dear Mr. Shano:
The Food and Drug Administration (FDA) has completed an evaluation of your firm’s corrective actions in response to our Warning Letter: 320-16-24 dated August 4, 2016. Based on our evaluation, it appears that you have addressed the deviations contained in this Warning Letter. Future FDA inspections and regulatory activities will further assess the adequacy and sustainability of these corrections.
This letter does not relieve you or your firm from the responsibility of taking all necessary steps to assure sustained compliance with the Federal Food, Drug, and Cosmetic Act and its implementing regulations or with other relevant legal authority. The FDA expects you and your firm to maintain compliance and will continue to monitor your state of compliance. This letter will not preclude any future regulatory action should deviations be observed during a subsequent inspection or through other means.
Sincerely,
/S/
Christina Alemu-Cruickshank
Compliance Officer
Division of Drug Quality I